title: Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy.
abstract: Dendritic cells (DC) are increasingly explored as cellular vaccines for tumor immunotherapy. In most reported DC-based cancer vaccine trials, DC have been pulsed with soluble tumor antigen-derived peptide ligands of MHC molecules. Considering that the half-life of peptide/MHC complexes on the cell surface is relatively short and that soluble exogenous protein antigens cannot be efficiently processed via the MHC class I-processing pathway, the current vaccination procedure is not optimal for the induction of strong T cell responses aiming at tumor rejection. Recently, we have shown that antigen presentation can be prolonged when synthetic peptides were encapsulated in biodegradable poly(D,L-lactide-co-glycolide) (PLGA) microspheres (MS) for uptake by DC. In the present study, we investigated the phenotypic and functional consequences of MS uptake by human monocyte-derived dendritic cells (MoDC) in vitro. We found that immature MoDC that were prepared in serum free media suitable for clinical application were able to phagocytose high numbers of MS, while matured MoDC showed a reduced capacity for phagocytosis of MS. The ingestion of MS did not change the cell surface expression of CD80, CD83, CD86 and HLA-DR of immature and mature DC, suggesting that MS uptake did not induce DC maturation but that maturation by cytokines or LPS was unaltered in the presence of MS. Furthermore, MS-loaded mature MoDC expressed normal levels of the chemokine receptor CCR7 and migrated as efficiently towards CCL19 or CCL21 as unloaded MoDC. DC viability and the secretion of TNF-alpha and IL-12 was not significantly changed by MS loading. Taken together, our data indicate that PLGA-MS loading has no negative effects on the pivotal properties of MoDC in vitro. It should therefore be feasible to further develop this antigen loading strategy for clinical use in immunotherapy against viral infections and tumors.
authors.affiliation: Research Department, Cantonal Hospital St. Gallen, CH-9007 St. Gallen, Switzerland.
authors.forename: Ying
authors.initials: Y
authors.lastname: Waeckerle-Men
authors.forename: Elke
authors.initials: E
authors.lastname: Scandella
authors.forename: Edith
authors.initials: E
authors.lastname: Uetz-Von Allmen
authors.forename: Burkhard
authors.initials: B
authors.lastname: Ludewig
authors.forename: Silke
authors.initials: S
authors.lastname: Gillessen
authors.forename: Hans P
authors.initials: HP
authors.lastname: Merkle
authors.forename: Bruno
authors.initials: B
authors.lastname: Gander
authors.forename: Marcus
authors.initials: M
authors.lastname: Groettrup
mesh_terms: D020341:Absorbable Implants; D017951:Antigen Presentation / Q000276:immunology; D017209:Apoptosis / Q000276:immunology; D002454:Cell Differentiation / Q000276:immunology*; D019070:Cell Lineage; D002465:Cell Movement / Q000276:immunology; D002470:Cell Survival; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008213:Lymphocyte Activation / Q000276:immunology; D008863:Microspheres; D009000:Monocytes / Q000166:cytology; D010587:Phagocytosis / Q000276:immunology*; D010641:Phenotype; D011098:Polyglactin 910
chemical_list: D016207:Cytokines; D011098:Polyglactin 910